PortfoliosLab logoPortfoliosLab logo
XPH vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

XPH vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in SPDR S&P Pharmaceuticals ETF (XPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, XPH achieves a 0.66% return, which is significantly lower than IDNA's 10.31% return.


XPH

1D
1.10%
1M
-4.74%
YTD
0.66%
6M
4.44%
1Y
37.98%
3Y*
13.07%
5Y*
3.50%
10Y*
3.44%

IDNA

1D
0.73%
1M
-2.56%
YTD
10.31%
6M
8.52%
1Y
40.87%
3Y*
6.74%
5Y*
-8.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

XPH vs. IDNA - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
XPH
SPDR S&P Pharmaceuticals ETF
0.66%31.60%4.94%2.97%-9.83%-10.54%14.68%21.53%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
10.31%17.26%-0.72%-7.63%-42.28%-3.98%54.30%20.83%

Correlation

The correlation between XPH and IDNA is 0.76, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.76

Correlation (3Y)
Calculated over the trailing 3-year period

0.74

Correlation (5Y)
Calculated over the trailing 5-year period

0.74

Correlation (All Time)
Calculated using the full available price history since Jun 14, 2019

0.74

The correlation between XPH and IDNA has been stable across timeframes, ranging from 0.73 to 0.76 - a consistent structural relationship.

XPH vs. IDNA - Sectors Allocation Comparison


Sectors
XPH
IDNA

Healthcare

100.0%
97.8%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

-

Industrials

-

0.4%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

XPH
100.0%
IDNA
97.8%

Basic Materials

XPH

-

IDNA

-

Communication Services

XPH

-

IDNA

-

Consumer Cyclical

XPH

-

IDNA

-

Consumer Defensive

XPH

-

IDNA

-

Energy

XPH

-

IDNA

-

Financial Services

XPH

-

IDNA

-

Industrials

XPH

-

IDNA
0.4%

Real Estate

XPH

-

IDNA

-

Technology

XPH

-

IDNA

-

Utilities

XPH

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

XPH vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XPH
XPH Risk / Return Rank: 5555
Overall Rank
XPH Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
XPH Sortino Ratio Rank: 5151
Sortino Ratio Rank
XPH Omega Ratio Rank: 4646
Omega Ratio Rank
XPH Calmar Ratio Rank: 6464
Calmar Ratio Rank
XPH Martin Ratio Rank: 6363
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 5555
Overall Rank
IDNA Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 4949
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4242
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7676
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XPH vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


XPHIDNADifference
Sharpe ratioReturn per unit of total volatility

+0.09

Sortino ratioReturn per unit of downside risk

+0.07

Omega ratioGain probability vs. loss probability

1.30

1.27

+0.02

Calmar ratioReturn relative to maximum drawdown

3.19

3.85

-0.66

Martin ratioReturn relative to average drawdown

11.37

10.98

+0.40

XPH vs. IDNA - Sharpe Ratio Comparison

The current XPH Sharpe Ratio is 1.77, which is comparable to the IDNA Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of XPH and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


XPHIDNADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.77

1.68

+0.09

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.17

-0.30

+0.47

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.16

Sharpe Ratio (All Time)

Calculated using the full available price history

0.38

0.10

+0.28

Drawdowns

XPH vs. IDNA - Drawdown Comparison

The maximum XPH drawdown since its inception was -48.03%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for XPH and IDNA.


Loading charts...

Drawdown Indicators


XPHIDNADifference

Max Drawdown

Largest peak-to-trough decline

-48.03%

-68.26%

+20.23%

Max Drawdown (1Y)

Largest decline over 1 year

-11.97%

-10.66%

-1.31%

Max Drawdown (3Y)

Largest decline over 3 years

-23.57%

-29.73%

+6.16%

Max Drawdown (5Y)

Largest decline over 5 years

-31.63%

-68.26%

+36.63%

Max Drawdown (10Y)

Largest decline over 10 years

-35.97%

Current Drawdown

Current decline from peak

-7.22%

-45.61%

+38.39%

Average Drawdown

Average peak-to-trough decline

-17.25%

-36.24%

+18.99%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.35%

3.73%

-0.38%

Volatility

XPH vs. IDNA - Volatility Comparison

SPDR S&P Pharmaceuticals ETF (XPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) have volatilities of 7.03% and 7.18%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


XPHIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

7.03%

7.18%

-0.15%

Volatility (6M)

Calculated over the trailing 6-month period

16.77%

17.98%

-1.21%

Volatility (1Y)

Calculated over the trailing 1-year period

21.52%

24.48%

-2.96%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

20.84%

28.42%

-7.58%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.10%

29.53%

-7.43%

XPH vs. IDNA - Expense Ratio Comparison

XPH has a 0.35% expense ratio, which is lower than IDNA's 0.47% expense ratio.


Dividends

XPH vs. IDNA - Dividend Comparison

XPH's dividend yield for the trailing twelve months is around 0.66%, less than IDNA's 1.07% yield.


PositionTTM20252024202320222021202020192018201720162015
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.07%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%0.00%0.00%
XPH
SPDR S&P Pharmaceuticals ETF
0.66%0.83%1.58%1.28%1.64%0.95%0.47%0.64%0.65%0.67%0.63%7.15%

Frequently Asked Questions


XPH and IDNA have a correlation of 0.76, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.18%) compared to XPH (7.03%). In terms of maximum drawdown, XPH dropped -48.03% vs IDNA's -68.26%.

On 5-year performance, XPH leads with 3.50% vs -8.42% for IDNA. On fees, XPH is cheaper at 0.35% per year. On volatility, XPH has been the lower-risk option at 7.03%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, XPH has performed better with a 3.50% return vs -8.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

XPH is cheaper with a 0.35% expense ratio, compared with 0.47% for IDNA.

IDNA has the higher dividend yield at 1.07%, compared with 0.66% for XPH.

XPH tracks S&P Pharmaceuticals Select Industry Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: State Street and iShares. Their fees differ too: 0.35% for XPH and 0.47% for IDNA.

XPH currently has the higher Sharpe Ratio (1.77 vs 1.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for XPH and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer